Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announces its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD. LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.2,* Dry AMD is a progressive disease typically treated in late stage, with limited treatment options.
Read the full article: Alcon to Acquire LumiThera //
Source: https://www.businesswire.com/news/home/20250702399355/en/Alcon-to-Acquire-LumiThera-and-Its-Photobiomodulation-Device-for-the-Treatment-of-Early-and-Intermediate-Dry-Age-Related-Macular-Degeneration-AMD